Nanogen, Inc. (Nasdaq: NGEN),
developer of molecular and rapid diagnostic products, announced today that it
has signed an end user license agreement (EULA) with Quest Diagnostics for use
of the Company's proprietary MGB Probe technology in human in vitro diagnostic
testing. Under the licensing agreement, Quest Diagnostics will have rights to
use and sell products and services incorporating the MGB Probe technology. Terms
of the EULA include an upfront fee and royalties paid on tests sold using the
licensed technology.
“We’re proud that Quest Diagnostics, the world’s leader in
diagnostic testing, is using our proprietary minor groove binder (MGB) technology
and incorporating it into some of their laboratory developed molecular tests,”
said Merl Hoekstra, Nanogen’s Vice President of Corporate and Business
Development. “We’re proud of the growing reputation and the expanding
base of licensed end users of our technology.”
The Company’s MGB Probe technology is broadly licensed in the research
and clinical fields and accounts for a majority of the Company’s revenue
today. Nanogen has more than 40 reagent and kit products sold for in vitro diagnostic
use under the MGB Alert® and Q-PCR Alert™ brands. End users who use
or would like to use our proprietary technology should contact our licensing
group to obtain a EULA.
Nanogen, Inc. develops diagnostic products that enable physicians to deliver
improved patient care. Its products allow faster and easier diagnosis, treatment
and monitoring of cardiovascular disease and a range of infectious diseases.
The company’s products include molecular diagnostic kits and reagents,
and kits for rapid point-of-care testing. Nanogen has pioneered the development
of biomarkers, molecular biology technologies and nanotechnology to bring better
results to diagnostics and healthcare. For additional information please visit
Nanogen’s website at www.nanogen.com.